Brief: Oncolytics Biotech® Receives FDA Fast Track Designation For The Treatment Of Advanced/Metastatic Pancreatic Cancer
01/12/2022 12:36
Dec 1 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® RECEIVES FDA FAST TRACK DESIGNATION
FOR THE
TREATMENT OF ADVANCED/METASTATIC PANCREATIC CANCER
Source text for Eikon: ID:nCNW3ScVva
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer